Abstract | IMPORTANCE: OBJECTIVE: DESIGN, SETTING, AND PATIENTS: An open-label, multicenter, randomized clinical trial in 49 intensive care units in France, February 2009-November 2011. In total, 130 patients were assessed for eligibility and 98 comatose adults (Glasgow Coma Scale [GCS] score of ≤8 for <12 hours) with community-acquired bacterial meningitis were randomized. INTERVENTIONS:
Hypothermia group received a loading dose of 4°C cold saline and were cooled to 32°C to 34°C for 48 hours. The rewarming phase was passive. Controls received standard care. MAIN OUTCOMES AND MEASURES: Primary outcome measure was the Glasgow Outcome Scale score at 3 months (a score of 5 [favorable outcome] vs a score of 1-4 [unfavorable outcome]). All patients received appropriate antimicrobial therapy and vital support. Analyses were performed on an intention-to-treat basis. The data and safety monitoring board (DSMB) reviewed severe adverse events and mortality rate every 50 enrolled patients. RESULTS: After inclusion of 98 comatose patients, the trial was stopped early at the request of the DSMB because of concerns over excess mortality in the hypothermia group (25 of 49 patients [51%]) vs the control group (15 of 49 patients [31%]; relative risk [RR], 1.99; 95% CI, 1.05-3.77; P = .04). Pneumococcal meningitis was diagnosed in 77% of patients. Mean (SD) temperatures achieved 24 hours after randomization were 33.3°C (0.9°C) and 37.0°C (0.9°C) in the hypothermia and control group, respectively. At 3 months, 86% in the hypothermia group compared with 74% of controls had an unfavorable outcome (RR, 2.17; 95% CI, 0.78-6.01; P = .13). After adjustment for age, score on GCS at inclusion, and the presence of septic shock at inclusion, mortality remained higher, although not significantly, in the hypothermia group (hazard ratio, 1.76; 95% CI, 0.89-3.45; P = .10). Subgroup analysis on patients with pneumococcal meningitis showed similar results. Post hoc analysis showed a low probability to reach statistically significant difference in favor of hypothermia at the end of the 3 planned sequential analyses (probability to conclude in favor of futility, 0.977). CONCLUSIONS AND RELEVANCE: TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00774631.
|
Authors | Bruno Mourvillier, Florence Tubach, Diederik van de Beek, Denis Garot, Nicolas Pichon, Hugues Georges, Laurent Martin Lefevre, Pierre-Edouard Bollaert, Thierry Boulain, David Luis, Alain Cariou, Patrick Girardie, Riad Chelha, Bruno Megarbane, Arnaud Delahaye, Ludivine Chalumeau-Lemoine, Stéphane Legriel, Pascal Beuret, François Brivet, Cédric Bruel, Fabrice Camou, Delphine Chatellier, Patrick Chillet, Bernard Clair, Jean-Michel Constantin, Alexandre Duguet, Richard Galliot, Frédérique Bayle, Hervé Hyvernat, Kader Ouchenir, Gaetan Plantefeve, Jean-Pierre Quenot, Jack Richecoeur, Carole Schwebel, Michel Sirodot, Marina Esposito-Farèse, Yves Le Tulzo, Michel Wolff |
Journal | JAMA
(JAMA)
Vol. 310
Issue 20
Pg. 2174-83
(Nov 27 2013)
ISSN: 1538-3598 [Electronic] United States |
PMID | 24105303
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Body Temperature
- Coma
- Early Termination of Clinical Trials
- Female
- Glasgow Coma Scale
- Humans
- Hypothermia, Induced
(adverse effects)
- Male
- Meningitis, Pneumococcal
(therapy)
- Middle Aged
- Severity of Illness Index
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|